AVATAR therapy for auditory verbal hallucinations in people with psychosis: a single-blind, randomised controlled trial

Tom Kj Craig, Mar Rus-Calafell, Thomas Ward, Julian P Leff, Mark Huckvale, Elizabeth Howarth, Richard Emsley, Philippa A Garety, Tom Kj Craig, Mar Rus-Calafell, Thomas Ward, Julian P Leff, Mark Huckvale, Elizabeth Howarth, Richard Emsley, Philippa A Garety

Abstract

Background: A quarter of people with psychotic conditions experience persistent auditory verbal hallucinations, despite treatment. AVATAR therapy (invented by Julian Leff in 2008) is a new approach in which people who hear voices have a dialogue with a digital representation (avatar) of their presumed persecutor, voiced by the therapist so that the avatar responds by becoming less hostile and concedes power over the course of therapy. We aimed to investigate the effect of AVATAR therapy on auditory verbal hallucinations, compared with a supportive counselling control condition.

Methods: We did this single-blind, randomised controlled trial at a single clinical location (South London and Maudsley NHS Trust). Participants were aged 18 to 65 years, had a clinical diagnosis of a schizophrenia spectrum (ICD10 F20-29) or affective disorder (F30-39 with psychotic symptoms), and had enduring auditory verbal hallucinations during the previous 12 months, despite continued treatment. Participants were randomly assigned (1:1) to receive AVATAR therapy or supportive counselling with randomised permuted blocks (block size randomly varying between two and six). Assessments were done at baseline, 12 weeks, and 24 weeks, by research assessors who were masked to therapy allocation. The primary outcome was reduction in auditory verbal hallucinations at 12 weeks, measured by total score on the Psychotic Symptoms Rating Scales Auditory Hallucinations (PSYRATS-AH). Analysis was by intention-to-treat with linear mixed models. The trial was prospectively registered with the ISRCTN registry, number 65314790.

Findings: Between Nov 1, 2013, and Jan 28, 2016, 394 people were referred to the study, of whom 369 were assessed for eligibility. Of these people, 150 were eligible and were randomly assigned to receive either AVATAR therapy (n=75) or supportive counselling (n=75). 124 (83%) met the primary outcome. The reduction in PSYRATS-AH total score at 12 weeks was significantly greater for AVATAR therapy than for supportive counselling (mean difference -3·82 [SE 1·47], 95% CI -6·70 to -0·94; p<0·0093). There was no evidence of any adverse events attributable to either therapy.

Interpretation: To our knowledge, this is the first powered, randomised controlled trial of AVATAR therapy. This brief, targeted therapy was more effective after 12 weeks of treatment than was supportive counselling in reducing the severity of persistent auditory verbal hallucinations, with a large effect size. Future multi-centre studies are needed to establish the effectiveness of AVATAR therapy and, if proven effective, we think it should become an option in the psychological treatment of auditory verbal hallucinations.

Funding: Wellcome Trust.

Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile Numbers lost to follow-up are cumulative in relation to the total allocated at the start of the study.
Figure 2
Figure 2
Week 12 effect estimates and 95% CIs Forest plot shows standardised Cohen's d effect sizes for AVATAR versus supportive counselling. Positive effect favours AVATAR therapy. All scales reversed, except for VAAS and MANSA. PSYRATS-AH= Psychotic Symptoms Rating Scales–Auditory Hallucinations. BAVQ-R=Beliefs About Voices Questionnaire. VAAS=Voice Acceptance and Action Scale. VPDS=Voice Power Differential Scale. DASS-21=Depression Anxiety and Stress Scale. PSYRATS–DEL=Psychotic Symptoms Rating Scales–Delusions. SAPS=Scale for Assessment of Positive Symptoms. SANS=Scale for Assessment of Negative Symptoms. MANSA=Manchester Quality of Life. MAP=Maudsley Addiction Profile.
Figure 3
Figure 3
PSYRATS–AH total, distress, and frequency scores

References

    1. Hayward M, Jones AM, Bogen-Johnston L, Thomas N, Strauss C. Relating Therapy for distressing auditory hallucinations: a pilot randomized controlled trial. Schizophr Res. 2017;183:137–142.
    1. van der Gaag M, Valmaggia LR, Smit F. The effects of individually tailored formulation-based cognitive behavioural therapy in auditory hallucinations and delusions: a meta-analysis. Schizophr Res. 2014;156:30–37.
    1. Waters F, Allen P, Aleman A. Auditory hallucinations in schizophrenia and nonschizophrenia populations: a review and integrated model of cognitive mechanisms. Schizophr Bull. 2012;38:683–693.
    1. Aleman A, Laroi F. Insights into hallucinations in schizophrenia: novel treatment approaches. Expert Rev Neurother. 2011;11:1007–1015.
    1. Haddock G, Eisner E, Boone C, Davies G, Coogan C, Barrowclough C. An investigation of the implementation of NICE-recommended CBT interventions for people with schizophrenia. J Ment Health. 2014;23:162–165.
    1. Chadwick P, Birchwood M. The omnipotence of voices—a cognitive approach to auditory hallucinations. Brit J Psychiat. 1994;164:190–201.
    1. Birchwood M, Michail M, Meaden A. Cognitive behaviour therapy to prevent harmful compliance with command hallucinations (COMMAND): a randomised controlled trial. Lancet Psychiatry. 2014;1:23–33.
    1. Paulik G. The role of social schema in the experience of auditory hallucinations: a systematic review and a proposal for the inclusion of social schema in a cognitive behavioural model of voice hearing. Clin Psychol Psychother. 2012;19:459–472.
    1. Longden E, Corstens D, Escher S, Romme M. Voice hearing in a biographical context: a model for formulating the relationship between voices and life history. Psychosis. 2012;4:224–234.
    1. Leff J, Williams G, Huckvale MA, Arbuthnot M, Leff AP. Computer-assisted therapy for medication-resistant auditory hallucinations: proof-of-concept study. Br J Psychiatry. 2013;202:428–433.
    1. Craig TK, Rus-Calafell M, Ward T. The effects of an Audio Visual Assisted Therapy Aid for Refractory auditory hallucinations (AVATAR therapy): study protocol for a randomised controlled trial. Trials. 2015;16:349.
    1. Craig T, Ward T, Rus-Calafell M. AVATAR therapy for refractory auditory hallucinations. In: Pradhan B, Pinninti N, Rathod S, editors. Brief interventions for psychosis: a clinical compendium. Springer; London: 2016.
    1. Lewis S, Tarrier N, Haddock G. Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. Br J Psychiatry Suppl. 2002;43:s91–e97.
    1. Rogers CR. The necessary and sufficient conditions of therapeutic personality change. J Consult Psychol. 1957;21:95–103.
    1. Hill A. BACP; London: 2011. Curriculum for counselling for depression. / (accessed Nov 3, 2017).
    1. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS) Psychol Med. 1999;29:879–889.
    1. Woodward TS, Jung K, Hwang H. Symptom dimensions of the psychotic symptom rating scales in psychosis: a multisite study. Schizophr Bull. 2014;40(Suppl):S265–S274.
    1. Chadwick P, Lees S, Birchwood M. The revised Beliefs About Voices Questionnaire (BAVQ-R) Brit J Psychiat. 2000;177:229–232.
    1. Shawyer F, Ratcliff K, Mackinnon A, Farhall J, Hayes SC, Copolov D. The voices acceptance and Action Scale (VAAS): pilot data. J Clin Psychol. 2007;63:593–606.
    1. Birchwood M, Meaden A, Trower P, Gilbert P, Plaistow J. The power and omnipotence of voices: subordination and entrapment by voices and significant others. Psychol Med. 2000;30:337–344.
    1. Andreasen NC. The University of Iowa; Iowa City: 1984. The scale for the assessment of positive symptoms (SAPS)
    1. Lovibond PF, Lovibond SH. The structure of negative emotional states—comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995;33:335–343.
    1. Addington D, Addington J, Matickatyndale E. Assessing depression in schizophrenia—the Calgary Depression Scale. Brit J Psychiat. 1993;163:39–44.
    1. Rosenberg M. Princeton University Press; Princeton: 1965. Society and the adolescent self-image.
    1. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA) Int J Soc Psychiatr. 1999;45:7–12.
    1. Marsden J, Gossop M, Stewart D. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998;93:1857–1867.
    1. McCarthy-Jones S, Trauer T, Mackinnon A, Sims E, Thomas N, Copolov DL. A new phenomenological survey of auditory hallucinations: evidence for subtypes and implications for theory and practice. Schizophr Bull. 2012;40:231–235.
    1. Gold SM, Enck P, Hasselmann H. Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework. Lancet Psychiatry. 2017;4:725–732.
    1. Turner DT, van der Gaag M, Karyotaki E, Cuijpers P. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiat. 2014;171:523–538.

Source: PubMed

3
Tilaa